# Resource Summary Report

Generated by RRID on Aug 30, 2026

## KLN205

RRID:CVCL_3533
Type: Cell Line

### Proper Citation

ECACC Cat# 90110519, RRID:CVCL_3533

### Cell Line Information

**URL:** https://web.expasy.org/cellosaurus/CVCL_3533

**Proper Citation:** ECACC Cat# 90110519, RRID:CVCL_3533

**Description:** Cell line KLN205 is a Cancer cell line with a species of origin Mus musculus (Mouse)

**Sex:** Male

**Disease:** Squamous cell carcinoma of the mouse pulmonary system

**Defining Citation:** PMID:418873, PMID:7419233

**Comments:** Karyotypic information: Tetraploid karyotype with 77-82 chromosomes per cell (DOI=10.20517/2394-4722.2021.59)., Characteristics: Tumorigenic. Forms metastatic lesions in lungs after inoculation into mice (CLS=400419).

**Category:** Cancer cell line

**Organism:** Mus musculus (Mouse)

**Name:** KLN205

**Synonyms:** KLN 205, KLN-205

**Cross References:** BTO:BTO_0001589, CLO:CLO_0007105, CLO:CLO_0050214, CLDB:cl3032, ATCC:CRL-1453, BCRC:60207, CLS:400419, ECACC:90110519, RCB:RCB2623, TKG:TKG 0214, Wikidata:Q54900028

**ID:** CVCL_3533

**Vendor:** ECACC

**Catalog Number:** 90110519

**Record Creation Time:** 20220427T220704+0000

**Record Last Update:** 20260829T234417+0000

## Ratings and Alerts

No rating or validation information has been found for KLN205.

No alerts have been found for KLN205.

## Data and Source Information

**Source:** Cellosaurus

## Usage and Citation Metrics

We found 5 mentions in open access literature.

**Listed below are recent publications.** The full list is available at RRID .

Sumii M, et al. (2026) Plasminogen Activator Inhibitor-1 Mediates Tolerance to Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer. Molecular cancer therapeutics, 25(3), 435.

Ataeinia B, et al. (2025) LAMP1 as a Target for PET Imaging in Adenocarcinoma Xenograft Models. Pharmaceuticals (Basel, Switzerland), 18(8).

Saini M, et al. (2025) StealTHY: An immunogen-free CRISPR platform to expose concealed metastasis regulators in immunocompetent models. Cell, 188(26), 7591.

Yabuki Y, et al. (2024) Hypoxia-inducible factor-targeting therapy augmented the sensitivity to programmed death ligand-1 blockade by enhancing interferon-??-induced chemokines in tumor cells. International journal of cancer.

Gozgit JM, et al. (2021) PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity. Cancer cell, 39(9), 1214.